The GLIX1 Phase 1/2a catalyst (first patient dosed) and ASCO abstracts provide near-term upside potential for a $14M market cap stock, but the going concern risk and $403M accumulated deficit cap the upside. Monitor H2 2026 GLIX1 updates and the CheMo4METPANC interim analysis for PDAC. The cash runway into H1 2027 suggests no near-term financing urgency, but the company will likely need to raise capital before year-end 2026.
Price Chart
Executive Summary
BioLineRx reported Q1 2026 results: royalty revenues of $0.5M (up from $0.3M YoY) but operating loss widened to $3.0M from $2.4M, driven by a 55.8% increase in R&D expenses for the GLIX1 program. Net loss was $2.6M vs net income of $5.1M in Q1 2025 (which included a $7.6M non-cash warrant fair-value gain). The company dosed the first patient in a Phase 1/2a GLIX1 trial for glioblastoma and maintains cash runway into H1 2027. However, the filing explicitly discloses a material uncertainty about going concern, with $403M accumulated deficit and negative operating cash flow.
Key Facts
- Q1 2026 royalty revenues $0.5M, up from $0.3M YoY, driven by APHEXDA royalties from Ayrmid
- Operating loss widened to $3.0M from $2.4M YoY, with R&D expenses up 55.8% to $2.5M due to GLIX1
- Net loss of $2.6M vs net income of $5.1M in Q1 2025 (which included $7.6M non-cash warrant gain)
- Cash, cash equivalents and short-term deposits of $17.4M as of March 31, 2026
- First patient dosed in Phase 1/2a GLIX1 trial for glioblastoma; updates expected H2 2026
- Accumulated deficit of $403M through March 31, 2026; going concern uncertainty disclosed
- Net cash used in operating activities was $2.3M in Q1 2026, slightly improved from $2.6M YoY
- Loan repayments of $1.12M in Q1 2026; total debt outstanding $7.8M (current + non-current)
Financial Impact
Q1 2026 net loss of $2.6M vs net income of $5.1M YoY; cash burn $2.3M from operations; $17.4M cash runway into H1 2027
Risk Factors
- Going concern uncertainty with $403M accumulated deficit and negative operating cash flow
- Dependence on GLIX1 clinical success for future value; Phase 1/2a is early-stage with binary risk
- Limited cash runway into H1 2027; likely need for dilutive financing before end of 2026
- Geopolitical risk from Israel conflicts; temporary ceasefire may not hold
- Gloria license partner not advancing PDAC study in China as planned
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-002934 |
| Exhibit: exhibit_1.htm | 0001178913-26-002934 |
| Exhibit: exhibit_3.htm | 0001178913-26-002934 |
| Document: zk2635421.htm | 0001178913-26-002934 |
| Document: 0001178913-26-002934-index-headers.html | 0001178913-26-002934 |
| Document: 0001178913-26-002934-index.html | 0001178913-26-002934 |
| Document: 0001178913-26-002934.txt | 0001178913-26-002934 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.04 | awaiting T+20 | — | $2.03 (−0.49%) |
Oct 5, 2026 22d ago | EFFECT | $2.32 | awaiting T+20 | — | $2.03 (+12.50%) |
Sep 25, 2026 4w ago | F-1 | $2.43 $2.00 | ▼ −17.70% | ▼ −17.66% | $2.03 (−16.46%) |
Sep 10, 2026 6w ago | 6-K | $2.57 $2.21 | ▼ −13.99% | ▼ −16.12% | $2.03 (−21.00%) |
Aug 31, 2026 8w ago | 424B5 | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 28, 2026 8w ago | 6-K | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.03 (+21.92%) |
Aug 28, 2026 8w ago | Press Release | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.03 (+21.92%) |
Jul 8, 2026 15w ago | 6-K | $3.01 $2.72 | ▼ −9.73% | ▼ −13.01% | $2.03 (−32.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers